Produit
AGENTS IA
APPLICATIONS DE L'IA
AUTRES
Solutions
SECTEURS D'ACTIVITÉ
USE CASES
Tarification
Ressources
EXPLORER
ENGAGER
ASSISTANCE ET SERVICES
À propos
Plateforme PatSnap Eureka
Mandataires en propriété intellectuelle
Agents pour l'ingénierie
Agents pour les sciences de la vie
Agents pour matériaux
PatSnap Eureka Desktop
NEWAnalytique
Intelligence IPSynapse
Renseignement biopharmaceutiqueBiographie
Recherche et analyse de séquences biologiquesChimique
Recherche et analyse de structures chimiquesPlateforme ouverte
NEWServices professionnels
Cabinets d'avocats
Sciences de la vie
Haute technologie
Competitor Tech Research
Design Risk Screening
Telecom SEP Claim Chart
Accès à plus de 2 000 000 000 points de données structurées dans les domaines des brevets, des sciences, des litiges et des technologies.
Innovez 75 % plus vite à un coût réduit de 25 %.
Cloud ou sur site pour une confidentialité et un contrôle maximaux
Reconnu par plus de 18 000 innovateurs à travers le monde
Pour l'utiliser, cliquez sur le bouton de vérification dans l'e-mail que nous avons envoyé à [email protected].
Cela contribue à sécuriser votre compte.
Vous devriez le recevoir sous peu. N'oubliez pas de vérifier votre dossier spam.
Unlock professional features and history
Already have an account? Log In
To start using PatSnap Eureka, click the verification button in the email we sent to .
This helps keep your account secure.
Haven't received it? Check your spam folder.
Série soigneusement sélectionnée offrant des informations précieuses aux professionnels de l'innovation.
Article | Rapport From STELLAR's Phase III results to HYPERION and ZENITH: how sotatercept is reshaping PAH treatment across all risk strata and disease stages.
Article | Rapport Explore the key engineering, operational, and infrastructure tradeoffs between hydrogen fuel cell and battery-electric powertrains for long-haul heavy-duty trucking.
Article | Rapport Pelacarsen's HORIZON Phase III trial is the first cardiovascular outcomes study for Lp(a) lowering. Explore the mechanism, trial design, and competitive landscape.
Article | Rapport How does silicon photonics differ from traditional fiber optics for data center interconnects? Engineering breakdown of integration, bandwidth, and cost trade-offs.
Article | Rapport What engineering challenges must be solved to build a 10MW floating offshore wind turbine? Structural dynamics, mooring, control, and installation — analysed.
Article | Rapport Cobenfy (xanomeline-trospium) leads a crowded muscarinic agonist pipeline for schizophrenia and Alzheimer's psychosis. Explore competitive readouts, key players, and patent trends for 2026.
Article | Rapport ViTs vs CNNs for industrial defect detection: how global self-attention compares to local convolution across accuracy, speed, and data requirements.
Article | Rapport Fazirsiran, ARO-AAT, and gene therapy are reshaping the AATD drug pipeline. Explore Phase 2 data, GalNAc delivery, and what Phase 3 means for liver disease.
Article | Rapport Key engineering considerations for MRI-compatible medical device design: material selection, lead safety, RF shielding, and adaptive implant strategies. Evidence from 50+ patents.
Article | Rapport Anito-cel, cilta-cel, ide-cel and next-generation BCMA CAR-T therapies in multiple myeloma: competitive landscape, IP strategy, and clinical signals analysed.
Article | Rapport How do synchronous and asynchronous motor drives differ for industrial efficiency? A patent-backed analysis covering control architecture, slip losses, and hybrid drive trends.
Article | Rapport Anito-cel, cilta-cel, ide-cel, and next-gen BCMA CAR-T in multiple myeloma: IP strategy, clinical signals, dual-targeting innovations, and the Gilead/Arcellx competitive landscape.
Article | Rapport Explore the 2026 green ammonia synthesis technology landscape: electrochemical, plasma, photocatalytic and next-gen Haber-Bosch routes mapped by patent activity.
Article | Rapport Examine the main reliability challenges of GaN power devices in automotive-grade applications: trapping, gate stack failure, short-circuit robustness, and more.
Article | Rapport How do orforglipron, oral semaglutide, and CagriSema compare in obesity and T2D? Analyse mechanisms, clinical signals, and IP strategy in the oral GLP-1 race.